- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06024759
Predictors of Risk in Left Ventricular Non-Compaction
Long Term Registry of Patients With Left Ventricular Non-Compaction and Predictors of Adverse Outcomes
The goal of this study is to learn more about the risk factors associated with left ventricular non-compaction (LVNC) and the predictors of adverse outcomes associated with LVNC. The main questions this study aims to answer are as follows.
- Are there any genetic mutations that impact the risk of LVNC patients developing ventricular arrhythmias?
- Does LV myocardial strain increase risk stratification in the LVNC population with or without genetic mutations?
- What are some of the determinants that cause LV dysfunction in LVNC?
- What are other risk stratifiers (ex. premature ventricular contraction (PVC) burden on Holter, non-sustained ventricular tachycardia (NSVT) on stress test) that lead to an outcome of ICD implantation?
Participants will have their medical records accessed annually for a span of ten years, either prospectively or retrospectively depending on whether they are being actively followed by physicians at the Inherited Arrhythmia Clinic or not, to evaluate LVNC progression over time. This data will be stored in a large clinical registry with the London Heart Rhythm Program at the London Health Sciences Centre, University Hospital Campus.
Study Overview
Status
Conditions
Detailed Description
Left ventricular noncompaction (LVNC) is a congenital cardiomyopathy in which the left ventricle (LV) of the heart does not develop properly due to impaired myocardial compaction. In utero, cardiac muscle is initially sponge-like, eventually becoming smooth and firm through a process termed compaction. Specifically, in LVNC, impairment of compaction leads to the distal portion of the LV myocardium being thicker and more sponge-like than normal. Hypertrabeculation of the myocardium, where pieces of the heart muscle extend into the LV, result in blood-filled trabeculae and intertrabecular recesses forming within the inner endocardial wall. Collectively, this impairs the LV's ability to pump oxygenated blood throughout the body.
Although various strategies are used to manage LVNC once diagnosed, the severity of comorbidities caused by LVNC, including but not limited to atrial fibrillation, embolism, or stroke, warrant further investigation into the risk factors, etiology and management of LVNC. Furthermore, patients with a definitive diagnosis of LVNC are at an elevated risk of experiencing sudden cardiac arrest (SCA) or sudden cardiac death (SCD). However, little is known about risk stratification with regards to LVNC that can result in SCA or SCD, further highlighting the need for greater analysis of the risk factors implicated in this disease state.
Ultimately, a holistic understanding of the risk factors of LVNC and subsequent morbidities it causes is needed to help improve the diagnosis, treatment and management of patients with LVNC. Hence, the goal of this study is to evaluate the risk factors and mutations associated with cardiovascular events in patients with a confirmed diagnosis of LVNC who have preserved cardiac function.
This study aims to further investigate the risk factors associated with the onset and development of LVNC. Specifically, data will be collected from retrospective and prospective patients. The retrospective cohort consists of patients who are no longer being actively followed by physicians at the Inherited Arrhythmia Clinic at the London Health Sciences Centre, University Hospital Campus, whose data will be collected annually from their medical records from the past ten years. The prospective cohort consists of patients who are being actively followed by physicians at the Inherited Arrhythmia Clinic who, once consented and enrolled, will have their charts accessed annually for the next ten years.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Dr. Habib Khan
- Phone Number: 519-663-3746
- Email: habib.khan@lhsc.on.ca
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A5A5
- Recruiting
- London Health Sciences Centre - University Hospital
-
Contact:
- Dr. Habib Khan
- Phone Number: 519-663-3746
- Email: habib.khan@lhsc.on.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria
Patients must meet the following criteria in order to be included in the study.
- Have a confirmed diagnosis of LVNC (between 2010-2020 for patients in the retrospective cohort only)
- Be over 18 years of age
Exclusion Criteria
Patients are ineligible to participate in this study if they do not meet one or more of the inclusion criterion or if they have any other cardiomyopathy aside from LVNC that is linked to a genetic mutation they carry.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Retrospective Cohort
Individuals in this group were previously seen by physicians at the Inherited Arrhythmia Clinic at University Hospital, London Health Sciences Centre, yet are no longer being actively followed here anymore.
These patients will have their data retrospectively obtained annually, ten years into the past, to collect data on key variables providing insight on LVNC progression over time.
|
|
Prospective Cohort
Patients being actively followed up by physicians at the Inherited Arrhythmia Clinic will be approached either in person or via e-mail for consent and enrollment into this study.
These patients will have their medical charts accessed annually to collect data on key variables providing insight on LVNC progression over time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Develop a large clinical registry linked with the Inherited Arrhythmia Clinic
Time Frame: Up to 10 years
|
The Inherited Arrhythmia Clinic is a subdivision of the London Heart Rhythm Program at University Hospital, London Health Sciences Centre.
As such, data will not go offsite but will simply be stored in a local REDCap database.
|
Up to 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identification of genetic mutations linked to LVNC
Time Frame: Up to 10 years
|
Enrolled patient's will have their genetic test results thoroughly reviewed (if applicable) to better understand their involvement in the onset and progression of LVNC.
|
Up to 10 years
|
|
Identification of determinants that cause LV dysfunction
Time Frame: Up to 10 years
|
Enrolled patient's will have their medical charts accessed to identify factors contributing to LV dysfunction in patients with LVNC.
|
Up to 10 years
|
|
Identification of factors that lead to ICD implantation
Time Frame: Up to 10 years
|
Enrolled patient's will have their medical charts accessed to identify risk factors that lead to ICD implantation (if applicable) in patients with LVNC.
|
Up to 10 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 13529
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Left Ventricular Noncompaction
-
University of ZurichCompletedLeft Ventricular Noncompaction | Isolated Noncompaction of the Ventricular MyocardiumSwitzerland
-
University Hospital HeidelbergCharite University, Berlin, Germany; Goethe University; University Medicine Greifswald and other collaboratorsRecruitingAmyloidosis | HCM - Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Inflammatory Cardiomyopathy | DCM - Dilated Cardiomyopathy | Non-ischemic Cardiomyopathy | HOCM - Hypertrophic Obstructive Cardiomyopathy | Left Ventricular Noncompaction CardiomyopathyGermany
-
Ceric SàrlNot yet recruitingLeft Ventricular Dysfunction | Left Ventricular (LV) Systolic Dysfunction | Left Ventricular Cardiac Dysfunction | Left Ventricular Ejection Fraction | Tricuspid Insufficiency | Tricuspid Regurgitation (TR)
-
Mayo ClinicNot yet recruitingMenopause | Left Ventricular DysfunctionUnited States
-
University of LeipzigCompletedLeft Ventricular Hypertrophy | Left Ventricular Failure | Left Ventricular Non-compaction CardiomyopathyGermany
-
Lawson Health Research InstituteMedtronicTerminatedHeart Failure, Left Ventricular DysfunctionCanada
-
AstraZenecaCompletedLeft Ventricle FunctionSweden
-
Ataturk UniversityNot yet recruitingLeft Ventricular Dysfunction | Cardiopulmonary Bypass SurgeryTurkey (Türkiye)
-
Tri-Service General HospitalRecruitingLeft Ventricular (LV) Systolic DysfunctionTaiwan
-
Tulane UniversityJohns Hopkins UniversityRecruitingEndothelial Dysfunction | Vascular Stiffness | Left Ventricular Dysfunction | Left Ventricular HypertrophyUnited States